Assessing Indivior (NasdaqGS:INDV) Valuation After Recent Share Price Swings And DCF Upside Potential

Simply Wall St.01-18

AdvertisementEvent context and recent stock performance Indivior (INDV) has been on investors’ radar after recent share price swings, with the stock showing a 1 day return of 1.05% and a 7 day decline...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604929895?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-01-18 04:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604929895","market":"nz","top_or_hot":-1,"title":"Assessing Indivior (NasdaqGS:INDV) Valuation After Recent Share Price Swings And DCF Upside Potential","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementEvent context and recent stock performance Indivior (INDV) has been on investors’ radar after recent share price swings, with the stock showing a 1 day return of 1.05% and a 7 day decline...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/assessing-indivior-nasdaqgsindv-valuation-after-recent-share\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Indivior (NasdaqGS:INDV) Valuation After Recent Share Price Swings And DCF Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Indivior (NasdaqGS:INDV) Valuation After Recent Share Price Swings And DCF Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-18 04:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/assessing-indivior-nasdaqgsindv-valuation-after-recent-share><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementEvent context and recent stock performance Indivior (INDV) has been on investors’ radar after recent share price swings, with the stock showing a 1 day return of 1.05% and a 7 day decline...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/assessing-indivior-nasdaqgsindv-valuation-after-recent-share\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/assessing-indivior-nasdaqgsindv-valuation-after-recent-share","article_id":"2604929895","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/assessing-indivior-nasdaqgsindv-valuation-after-recent-share","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604929895","pubTimestamp":1768681653,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Event context and recent stock performance\nIndivior (INDV) has been on investors’ radar after recent share price swings, with the stock showing a 1 day return of 1.05% and a 7 day decline of 8.18%.\nOver the past month the share price return is a 9.49% decline, contrasting with a 32.92% gain over the past 3 months. This may prompt investors to reassess how current pricing lines up with Indivior’s fundamentals.\nSee our latest analysis for Indivior.\nAt a share price of US$32.54, Indivior’s...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","INDV":"INDIVIOR PLC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"在近期股价波动和DCF上涨潜力后评估Indivior（纳斯达克GS：INDV）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1.5,"INDV":1.5},"content_text":"AdvertisementEvent context and recent stock performance Indivior (INDV) has been on investors’ radar after recent share price swings, with the stock showing a 1 day return of 1.05% and a 7 day decline of 8.18%. Over the past month the share price return is a 9.49% decline, contrasting with a 32.92% gain over the past 3 months. This may prompt investors to reassess how current pricing lines up with Indivior’s fundamentals. See our latest analysis for Indivior. At a share price of US$32.54, Indivior’s recent 7 day and 30 day share price declines sit alongside a 1 year total shareholder return of around 2.8x. This suggests that recent momentum has cooled after a longer term run as investors reassess risk and growth expectations. If Indivior’s swings have you thinking about where else to put your capital to work, it could be a moment to scan other healthcare names with our healthcare stocks. With Indivior trading at US$32.54 alongside an implied discount to some valuation estimates, the key question is whether this represents a temporary pause in a longer story or a market that already prices in future growth. Price-to-Earnings of 32.8x: Is it justified? At a last close of US$32.54, Indivior trades on a P/E of 32.8x, which sits slightly below the peer average but above the wider pharmaceuticals group. The P/E ratio compares the company’s share price with its earnings per share and is a common way to see how much investors are paying for current profits in this sector. Indivior screens as good value versus its direct peers, with a P/E of 32.8x compared to a peer average of 34x. However, it looks expensive against the broader US pharmaceuticals industry on 20.8x. The current P/E also stands above an estimated fair P/E of 30x, a level the market could potentially move toward if enthusiasm around earnings eases. Explore the SWS fair ratio for Indivior Result: Price-to-Earnings of 32.8x (ABOUT RIGHT) However, you still need to weigh risks, such as concentrated exposure to opioid use disorder treatments and the possibility that earnings growth expectations embedded in a 32.8x P/E prove optimistic. Find out about the key risks to this Indivior narrative. Another view: what the DCF model suggests Our DCF model presents a very different picture, with an estimated fair value of around US$104.38 per share compared to the current US$32.54 price, indicating that Indivior may be trading at a large discount. That gap can suggest potential opportunity or simply highlight how sensitive long term forecasts are, so which side are you on? Look into how the SWS DCF model arrives at its fair value. INDV Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Indivior for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 863 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Indivior Narrative If you look at this data and reach a different conclusion, or simply prefer to test your own assumptions, you can build a custom view in just a few minutes with Do it your way. A great starting point for your Indivior research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision. Looking for more investment ideas? If you stop with just one company, you might miss other opportunities that suit your style, so give yourself options and keep your idea pipeline full.  Target potential value candidates by scanning these 863 undervalued stocks based on cash flows that line up with your view on cash flows and pricing. Spot income opportunities by checking out these 12 dividend stocks with yields > 3% that focus on yields above 3%. Explore digital asset themes by reviewing these 80 cryptocurrency and blockchain stocks tied to cryptocurrency and blockchain.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604929895","isCrawlerRequest":true}